Physician profile
Anjali Kohli
NPI 1811332265
$2,793.81
in general payments reported to CMS, 2019-2025
25 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $199 · 2022: $17.52 · 2023: $464 · 2024: $674 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $464.39 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $386.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $367.06 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $278.35 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $254.47 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $184.63 | 2023-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Janssen Scientific Affairs, LLC | $132.72 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $86.77 | 2024-2025 | Farxiga, Airsupra |
| Dynavax Technologies Corporation | $75.45 | 2023-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $72.21 | 2024-2025 | Inspire |
| Dexcom, INC. | $72.18 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $71.85 | 2025 | Lagevrio, Gardasil 9, Capvaxive |
| Ibsa Pharma INC. | $57.56 | 2025 | Licart, Tirosint, Flector |
| Sanofi Pasteur INC. | $47.07 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.99 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.35 | 2019-2022 | |
| Pfizer INC. | $28.66 | 2020-2024 | |
| Arbor Pharmaceuticals, INC. | $28.65 | 2019 | |
| Astellas Pharma US INC | $21.57 | 2024 | Veozah |
| Biogen, INC. | $18.74 | 2025 | Spinraza |
| Abbvie INC. | $18.59 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.39 | 2023 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $14.16 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.14 | 2019 | |
| Genentech USA, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Kohli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.